Menstrual Cycle Phases Alter Brain Reactivity to Drug Cues

The Neurobiology of Craving and the Push for Precision in Addiction Medicine

Substance use disorders are characterized by intense, cue-evoked cravings that frequently drive clinical relapse, a phenomenon deeply rooted in the dysregulation of the brain's reward circuits [1, 2]. For decades, researchers have utilized functional magnetic resonance imaging to measure how the brain reacts to drug-related stimuli, aiming to develop reliable biomarkers for addiction severity and treatment response [3]. Despite mapping consistent disruptions in regions like the prefrontal cortex and anterior cingulate, translating these neuroimaging findings into targeted, individualized therapies has proven difficult [4]. A major obstacle has been the historical tendency to overlook biological variables, particularly how sex and fluctuating hormones might alter the neural architecture of craving and cognitive control. A recent study demonstrates how the menstrual cycle directly modulates the brain's response to drug cues, highlighting a critical biological divergence in addiction neurobiology that could inform more precise treatment timing.

Mapping Sex Differences in the Addicted Brain

The underlying corticostriatal mechanisms (the neural pathways connecting the cerebral cortex to the striatum that govern reward processing and habit formation) of sex and hormonal effects in addiction are largely unknown, limiting the development of personalized treatments. To investigate these neurobiological differences, researchers utilized functional magnetic resonance imaging (MRI) to scan a cohort of 32 women (mean age 38.85 ± 9.84 years) diagnosed with either heroin use disorder (HUD, n = 16) or cocaine use disorder (CUD, n = 16). This female cohort was compared against 49 age-matched men (mean age 41.96 ± 9.71 years) diagnosed with HUD. The imaging data revealed distinct baseline differences in how male and female brains process addiction. Specifically, women showed higher medial prefrontal cortex (PFC) drug cue reactivity compared to men. In contrast, men showed higher frontal eye field (FEF) and dorsolateral PFC (dlPFC) drug reappraisal compared to women. Drug reappraisal refers to the cognitive ability to consciously regulate and suppress the urge to use a substance. Clinically, this enhanced regulatory capacity in male participants translated to better symptom control, as higher FEF and dlPFC drug reappraisal in men was associated with lower cue-induced drug craving. Overall, the findings demonstrate that compared with men with HUD, women with HUD or CUD show more corticostriatal drug cue reactivity and less PFC drug reappraisal activity. For practicing physicians, this baseline discrepancy suggests that female patients may experience a more intense neurological drive toward substance use coupled with a reduced intrinsic capacity to cognitively suppress those cravings, necessitating more robust behavioral support.

How the Menstrual Cycle Modulates Cognitive Control

To determine whether the observed sex differences in addiction neurobiology were static or influenced by hormonal fluctuations, the researchers conducted a longitudinal analysis. A subgroup of women (3 with heroin use disorder and 13 with cocaine use disorder) was scanned twice using functional MRI. These scans were precisely timed to occur during the late-follicular and mid-luteal phases of the menstrual cycle. The imaging data revealed a critical temporal dynamic. The researchers found that the effect of women showing more corticostriatal drug cue reactivity and less prefrontal cortex drug reappraisal activity is driven by the follicular compared with the luteal phase. This indicates that the heightened vulnerability to drug cues in female patients is not a constant baseline but rather fluctuates significantly with the menstrual cycle. Breaking down the phase-specific brain activity provided further clarity on how cognitive control shifts throughout the month. In women, drug cue reactivity was higher during the follicular phase in the frontal eye field and dorsolateral prefrontal cortex. This heightened reactivity aligns with a period of increased vulnerability to craving triggers. Conversely, during the luteal phase, female patients demonstrated an improved capacity for cognitive control. The scans showed that in women, drug reappraisal was higher during the luteal phase in the anterior prefrontal cortex and orbitofrontal cortex. For clinicians, this suggests that a female patient's neurological ability to consciously suppress the urge to use substances is biologically enhanced during the luteal phase, offering a potential window where cognitive behavioral therapies might be most effective.

Estrogen as a Vulnerability Factor, Progesterone as Protective

To understand the specific hormonal drivers behind these functional brain changes, the researchers analyzed how shifting endocrine profiles influenced neural activity. They determined that the phase-driven effect is directly related to craving and fluctuations in estrogen and progesterone. By measuring the difference (Δ) in hormone levels between the two cycle stages, the investigators mapped these fluctuations to specific corticostriatal regions. They found that the more the estradiol during the follicular versus luteal phase (Δ), the higher the Δdrug cue reactivity in the ventromedial PFC (vmPFC). This heightened neural response directly translated to clinical symptoms, as higher Δdrug cue reactivity in the vmPFC correlated with higher Δdrug craving. Additionally, the correlation between Δestradiol, Δdrug cue reactivity, and Δdrug craving was also observed in the inferior frontal gyrus. Beyond amplifying the urge to use substances, rising estrogen levels appeared to suppress the brain's regulatory networks. The imaging data demonstrated that the more the Δestradiol, the lower the Δdrug reappraisal in the vmPFC, anterior PFC, and striatum, leaving patients with a diminished capacity to cognitively manage their cravings. In contrast, the hormonal environment of the luteal phase facilitated better cognitive control over substance urges. The scans revealed that during the luteal versus follicular phase, the Δprogesterone/estradiol ratio was positively associated with Δdrug reappraisal in the dlPFC. This indicates that as progesterone levels rise relative to estrogen, the brain's ability to consciously suppress cravings improves. Synthesizing these neurobiological dynamics, the researchers concluded that estrogen constitutes a vulnerability factor for drug cue reactivity and craving, while progesterone constitutes a protective factor for drug cue reactivity and craving. For clinicians treating women with substance use disorders, these findings provide a clear biological rationale for why patients may experience predictable periods of high relapse risk.

Clinical Implications for Cycle-Timed Interventions

The neurobiological fluctuations observed in this study suggest that addiction management for female patients should not rely on a static, uniform approach. Because craving intensity and brain reactivity shift predictably alongside the menstrual cycle, clinicians must consider a patient's endocrine status when evaluating relapse risk. The imaging data demonstrate that the follicular phase, driven by rising estrogen, represents a period of heightened vulnerability to drug cues. Conversely, the progesterone-dominant luteal phase offers a natural window of enhanced cognitive control over substance urges. By recognizing these biological rhythms, physicians can begin to tailor interventions to match periods of peak neurological risk. Ultimately, the findings provide insights for developing precisely timed and hormonally informed treatments for women with HUD or CUD. In daily clinical practice, this could translate to scheduling more intensive behavioral therapies, increasing the frequency of outpatient visits, or adjusting pharmacological support specifically during the high-risk follicular phase to counteract the estrogen-driven spike in cue-induced craving.

References

1. Zheng Q, Song Y, Huang Y, Sun Y. 378. COMMON AND DISTINCT NEURAL SUBSTRATES OF CUE CRAVING RESPONSE BETWEEN SUBSTANCE AND BEHAVIORAL ADDICTION: A NEUROIMAGING META-ANALYSIS. International Journal of Neuropsychopharmacology. 2025. doi:10.1093/ijnp/pyaf052.053

2. Zhang X, Zhang H, Shao Y, Li Y, Zhang F, Zhang H. Common neural patterns of substance use disorder: a seed-based resting-state functional connectivity meta-analysis.. Translational psychiatry. 2025. doi:10.1038/s41398-025-03396-2

3. Sangchooli A, Zare-Bidoky M, Jouzdani AF, et al. Parameter Space and Potential for Biomarker Development in 25 Years of fMRI Drug Cue Reactivity: A Systematic Review.. JAMA psychiatry. 2024. doi:10.1001/jamapsychiatry.2023.5483

4. Ekhtiari H, Zare-Bidoky M, Sangchooli A, et al. A Methodological Checklist for fMRI Drug Cue Reactivity Studies: Development and Expert Consensus. medRxiv. 2020. doi:10.1101/2020.10.17.20214304